vidarabine phosphate and melphalan

vidarabine phosphate has been researched along with melphalan in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (25.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (50.00)	29.6817
2010's	1 (25.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bigner, DD; Friedman, HS; Schold, SC	1
Burnett, A; Dasgupta, RK; Davies, J; Jackson, G; Johnson, P; Morgan, GJ; Poynton, C; Richardson, C; Rule, S; Smith, GM; Stars, AC; Tollerfield, SM; Wareham, E; Wilson, K	1
Artz, A; De Lima, M; Giralt, S; Kunavakkam, R; Oran, B; Rondon, G; van Besien, K	1
Afkhami, M; Al Malki, MM; Aldoss, I; Ali, H; Aribi, A; Cao, T; Forman, SJ; Khaled, S; Marcucci, G; Mei, M; Mokhtari, S; Nakamura, R; O'Donnell, M; Pillai, R; Pullarkat, V; Salhotra, A; Snyder, D; Stein, AS; Yang, D; Yang, L	1

Trials

2 trial(s) available for vidarabine phosphate and melphalan

Article	Year
Fludarabine phosphate and melphalan: a reduced intensity conditioning regimen suitable for allogeneic transplantation that maintains the graft versus malignancy effect. Bone marrow transplantation, 2006, Volume: 37, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Infant; Male; Melphalan; Middle Aged; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine Phosphate	2006
Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2009, Volume: 15, Issue:5 Topics: Adolescent; Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Child; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Transplantation Conditioning; Treatment Outcome; Vidarabine Phosphate; Young Adult	2009

Article

Year

Fludarabine phosphate and melphalan: a reduced intensity conditioning regimen suitable for allogeneic transplantation that maintains the graft versus malignancy effect.

Bone marrow transplantation, 2006, Volume: 37, Issue:5

Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Infant; Male; Melphalan; Middle Aged; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine Phosphate

2006

Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2009, Volume: 15, Issue:5

Topics: Adolescent; Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Child; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Transplantation Conditioning; Treatment Outcome; Vidarabine Phosphate; Young Adult

2009

Other Studies

2 other study(ies) available for vidarabine phosphate and melphalan

Article	Year
Chemotherapy of subcutaneous and intracranial human medulloblastoma xenografts in athymic nude mice. Cancer research, 1986, Volume: 46, Issue:1 Topics: Animals; Azacitidine; Brain Neoplasms; Cell Line; Cytarabine; Doxorubicin; Humans; Medulloblastoma; Melphalan; Mice; Mice, Nude; Mitoguazone; Neoplasm Transplantation; Nitrosourea Compounds; Skin Neoplasms; Vidarabine Phosphate	1986
MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen. Blood advances, 2019, 01-08, Volume: 3, Issue:1 Topics: Adult; Aged; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Mutation; Primary Myelofibrosis; Prognosis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine Phosphate	2019

Article

Year

Chemotherapy of subcutaneous and intracranial human medulloblastoma xenografts in athymic nude mice.

Cancer research, 1986, Volume: 46, Issue:1

Topics: Animals; Azacitidine; Brain Neoplasms; Cell Line; Cytarabine; Doxorubicin; Humans; Medulloblastoma; Melphalan; Mice; Mice, Nude; Mitoguazone; Neoplasm Transplantation; Nitrosourea Compounds; Skin Neoplasms; Vidarabine Phosphate

1986

MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen.

Blood advances, 2019, 01-08, Volume: 3, Issue:1

Topics: Adult; Aged; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Mutation; Primary Myelofibrosis; Prognosis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine Phosphate

2019